Vicki L. Sato, Director at Denali Therapeutics Inc. (DNLI), sold 6,160 shares at $27.07 ($167K) on 2024-11-01, disclosed to the SEC on 2024-11-05.
Scheduled sale ($167k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.07 | 3,080 | $83K | 50.0% |
| 2 | $27.07 | 3,080 | $83K | 50.0% |
| Total | $27.07 avg | 6,160 | $167K | 100% |
| Filing → |
| VIR | SELL | 2026-03-03 | $416K | — | Filing → |
| VIR | SELL | 2026-02-26 | $825K | — | Filing → |
| VIR | SELL | 2026-02-03 | $170K | — | Filing → |